Erik de Blois

Erik de Blois is an Assistant Professor in the Department of Radiology & Nuclear Medicine at Erasmus MC, where he conducts cutting-edge research in targeted radionuclide therapy and radiopharmaceutical development. His work bridges radiochemistry, preclinical evaluation, and clinical implementation of novel alpha and beta-emitting therapies.

Research Interests: His primary research focuses on Actinium-225 and Lutetium-177 based therapies, particularly for prostate cancer and neuroendocrine tumors. He investigates chelator optimization, radiolysis mitigation, biodistribution, dosimetry, and quality control of radiopharmaceuticals. His fingerprint highlights expertise in Targeted Radionuclide Therapy, Radioisotopes, Prostate Specific Membrane Antigen, and Neoplasm.

Publication Trends: His recent publications (2022–2025) emphasize practical implementation of Ac-225 therapies, clinical experiences with PSMA-targeted agents, radiochemical optimization, and comparative studies of emerging radionuclides like Terbium-161. The research spans from bench to bedside, with a strong focus on safety, efficacy, and scalability of novel theranostic agents.

• Scientific Awards: No awards listed in the provided text.

Advising and Grants: While specific students or grants are not mentioned, his role as a principal investigator on multiple peer-reviewed publications and involvement in IAEA initiatives suggest active supervision and external funding acquisition. He collaborates extensively with national and international experts in nuclear medicine and radiochemistry.

Labs and Teams: He is part of a multidisciplinary team at Erasmus MC focused on advancing targeted alpha therapy, working closely with clinical and technical experts in nuclear medicine. His research contributes to the institution’s leadership in theranostics and personalized cancer treatment.